StockNews.AI
MLTX
StockNews.AI
1 min

MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

1. MLTX shares fell over 80% after negative trial results. 2. One trial met expectations but the second failed entirely. 3. Investors are encouraged to discuss legal options for losses. 4. The drug's commercial potential is now in doubt. 5. Securities firm probing potential claims against MoonLake.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant share drop and failed trials indicate a loss of investor confidence, similar to historical precedents in biotech where trial failures led to sustained declines.

How important is it?

The severe impact on share price and ongoing legal inquiries underpin a critical situation for investors, influencing MLTX's market position significantly.

Why Short Term?

With immediate market reactions, a short-term impact from the sell-off is expected, impacting investor sentiment quickly, as seen in similar biotech stock scenarios.

Related Companies

BRCRPFEABBV
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its shares plummet over 80% on Monday after disappointing results from two late-stage trials of its experimental drug, sonelokimab, for hidradenitis suppurativa. While one study showed a statistically significant improvement over placebo, the margin of benefit fell short of investor expectations. The second trial failed to meet its primary endpoint entirely, with the company citing an unexpectedly high placebo response. The underwhelming data has cast doubt on the drug's regulatory path and commercial potential, prompting skepticism from analysts and a sharp market sell-off. To learn more about the MoonLake investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cffc24f-1f2f-4a65-9fc1-400954361ba2

Related News